Document:

Exhibit
10.1

EMPLOYMENT
AGREEMENT BETWEEN REGEN BIOPHARMA, INC. AND THOMAS ICHIM

THIS EMPLOYMENT
AGREEMENT (the "Agreement") dated as of January 14, 2015 is entered into between Regen BioPharma,
Inc., a Nevada corporation, (the "Company") and Thomas Ichim ("Employee").

 

WITNESSETH:

WHEREAS, Employee
and the Company desire to enter into an agreement providing for the employment by the Company of Employee
upon the terms provided herein.

REPRESENTATIONS AND WARRANTIES:

 

A)
Company hereby represents and warrants to Employee as follows;

(i)
Corporate Existence of Company. Company:

(a)
is a corporation duly formed, validly existing and in good standing under the laws of the State of Nevada and

(b)
has all requisite power and authority, and has all governmental licenses, authorizations, consents and approvals necessary to
execute and deliver this Agreement and to consummate the transactions contemplated by this Agreement.

 

(ii) No
Conflicts. None of the execution, delivery and performance of this Agreement by Company, or the consummation
or the transactions contemplated hereby and thereby

 

(a)
constitute or will constitute a violation of the organizational documents of Company,

(b)
constitutes or will constitute a breach or violation of, or a default (or an event which, with notice
or lapse of time or both, would constitute such a default) under, any indenture, mortgage,
deed of Company, loan agreement, lease or other agreement or instrument to which Company is a
party or by which Company or any of its properties may be bound,

(c)
violates or will violate any statute, law or regulation or any order, judgment, decree or injunction of any court
or Governmental Authority directed to Company or any of its properties in a proceeding to which
its property is or was a party.

 

(B)
Employee hereby represents and warrant to Company as follows:

(i)
No Conflicts. None of the execution, delivery and performance of this Agreement by Employee, or the consummation of the transactions
contemplated hereby and thereby

(a)
constitutes or will constitute a breach or violation of, or a default (or an event which, with notice or lapse of time or both,
would constitute such a default) under, any indenture, mortgage, deed of Trust, loan agreement, lease or other agreement or instrument
to which Employee is a party or by which Employee or any of its properties may be bound,

(b)
violates or will violate any statute, law or regulation or any order, judgment, decree or injunction of any court or Governmental
Authority directed to Employee or any of their properties in a proceeding to which its property is or was a party.

AGREEMENT:

NOW,
THEREFORE, in consideration of the foregoing and the mutual promises and agreements set forth herein, the parties hereto, intending
to be legally bound, hereby agree as follows:

1.
Employment. During the Employment Period (as defined in Section 2), the Company hereby employs Employee and Employee hereby
accepts employment.

2.
Term. The Term of this Agreement shall commence on January 14, 2015 and shall expire on January 13, 2018 unless sooner terminated
in accordance with the provisions of Section 6 hereof; provided, however, that the term of this Agreement may be extended by mutual
agreement. The period from the commencement of the term of this Agreement to the date of its expiration or sooner termination
shall be considered to be the “Employment Period" hereunder.

3.
Duties. Employee shall be granted the title of Chief Scientific Officer of the Company subject to the authority of the Company's
Chief Executive Officer (the "CEO"), Employee shall perform such duties commensurate with his offices and as directed
by the CEO such duties to include, but not be limited to:

See
Schedule 1.

During
the Employment Period, Employee shall perform his duties hereunder in a diligent manner, subject to the provisions of Schedule
1 of this Agreement; devoting such amount of his business time, attention and efforts to the affairs of the Company within the
scope of his employment as is necessary for the proper rendition of such service and shall use his best efforts to promote the
best interests of the Company. Employee's services shall be rendered when and as required by the CEO and in accordance with his
instructions, direction and control.

It
is agreed that Employee will only devote such time as to effectively conduct duties and responsibilities associated with this
position pursuant to this Agreement.

4.
Compensation Salary. During the Employment Period, Company shall pay Employee salary at the rate of (i) $10,000 per month
prorated for any partial employment month ("Salary"). Salary shall be paid on a monthly basis (“Payday”)
or, in the event that Payday falls on a Saturday, Sunday or holiday, on the next business day. Salary may be paid, at the Company’s
sole discretion, either in

 

(a)
       cash, or

(b)
       shares of the Company’s common stock (“Stock Payment”)

 

Employee
acknowledges that any Stock Payments issued pursuant to this Agreement that are not registered pursuant to the Securities
Act of 1933 shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Securities
Act of 1933, and shall contain the following restrictive legend:

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS
OF ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM REGISTRATION UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

 

The
Company may register any Stock Payment pursuant to the Securities Act of 1933, but is not obligated to do so pursuant to this
Agreement.

 

5.
Benefits.

a.
During the Employment Period, Employee shall be entitled to participation in any profit sharing plan, retirement plan, group life
insurance plan or other insurance plan, medical expense plan, medical and dental insurance and other benefit arrangements maintained
by the Company for its employees generally and, if applicable, their family members. In addition, Employee shall be entitled to
two weeks paid vacation (“Vacation”) subject to (i) the completion of 12 full months of employment pursuant to this
Agreement and (ii) having given fourteen days prior notice to the Company of Employee’s intent to Vacation.

b.
Stock Compensation. Employee shall receive 6,000,000 newly issued common shares of the Company upon execution of this agreement
(“Signing Shares”). The shares shall be subject to a vesting schedule (see Schedule 2.).

Employee
acknowledges that any Signing Shares issued pursuant to this Agreement will not be registered pursuant to the Securities Act of
1933 , shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Securities
Act of 1933 and shall contain the following restrictive legend:

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

6.
Termination.

a.
Employee's employment hereunder shall terminate upon the earlier of:

(i)
the expiration of the Employment Period,

(ii)
the death of Employee,

(iii)
the expiration of a continuous period of thirty (30) calendar days during which Employee is unable to perform his material duties
due to physical or mental incapacity,

(iv)
termination by the Company due to “just cause,”

(v)
termination by Employee due to a material breach of this Agreement by the Company . The exercise of the right of the Company or
Employee to terminate this Agreement pursuant to clauses (iv) or (v) hereof, as the case may be, shall not abrogate the rights
and remedies of the terminating party in respect of the breach giving rise to such termination.

b.
"Just cause" hereunder shall be defined and limited to mean:

(i)
Employee's failure or refusal, as determined by either the CEO in his sole discretion, to perform specific directives of the CEO
which are consistent with the scope and nature of Employee's duties and responsibilities as set forth herein (including the duties
described in Section 3), which failure or refusal continues after notice thereof and a reasonable time to cure; such reasonable
time to be determined by the CEO.

(ii)
Employee's conviction for a felony or any crime involving moral turpitude, fraud, or misrepresentation, or the presentation of
proof satisfactory to the CEO in the exercise of its reasonable judgment of Employee's misappropriation or embezzlement of funds
or assets from the Company;

(iii)
any intentional act having the purpose and effect of injuring the reputation, business or business relationships of the Company
in any material respect; and

(iv)
any breach by Employee of any material provision of this Agreement, including, without limitation, the restrictive covenants contained
in Section 7 hereof.

c.
In the event of any dispute regarding the existence of Employee's incapacity hereunder, the matter wil1 be resolved by the determination
of a physician qualified to practice medicine in California selected by the CEO. For this purpose, Employee will submit to appropriate
medical examinations.

d.
If Employee's employment hereunder is terminated pursuant to Section 7, the Company shall have no further obligations or liabilities
hereunder.

7. Restrictive
Covenant.

a.
Non-disclosure. Employee has, and during the Employment Period will have, access to confidential information and trade secrets
of the Company and its subsidiaries (the "Confidential Information") that may include, among other things:

(i)
Financial information

(ii)
Supply and services information

(iii)
Marketing information

(iv)
Personnel information

(v)
Customer information

(vi)
Product information

(vii)
The Company’s procedures, systems, policies and processes of operation.

Employee
shall at all times during his employment by the Company and thereafter hold in strictest confidence any and all Confidential
Information that may have come or may come into Employee's possession or within Employee's knowledge. Employee agrees that
neither he nor any person or entity, directly or indirectly, controlled by or under common control with the Employee (an
"Affiliate")will for any reason, except in the course of performing his duties hereunder, for himself or any other
person, use or disclose to anyone, exclusive of Company employees, agents, representatives, or independent consultants to the
Company or any of its subsidiaries or Affiliates of the Company, any Confidential Information; provided, however, that
Employee may disclose Confidential Information which (i) has become generally available to the public other than as a result
of a breach of this Agreement by Employee or (ii) Employee is compelled to disclose pursuant to subpoena or an order by a
court competent jurisdiction; provided that, if Employee is so required to disclose any Confidential Information pursuant to
the foregoing clause (ii), Employee shall provide advance written notice to the Company, to the extent possible, to allow the
Company to seek an appropriate protective order therefore (iii) Potential advisors, employees, or investors of the Company
where there is a reasonable expectation of confidentiality. All Confidential Information shall remain the Company's property
and shall be returned (or, at the Company's option, destroyed) upon the Company's written request.

b.
Non-Solicitation of Employees. Employee agrees that from the date hereof and continuing for a period of three years following
the termination of this Agreement for whatever reason (the "Non-Compete Period"), neither Employee nor any Affiliate
of Employee will solicit or hire for employment any officer, director or employee of the Company who was employed by the Company
at any time within twelve months prior to the act of solicitation.

c.
Non-Competition. Employee agrees that, other than with the approval of the CEO, which approval shall not be unreasonably withheld,
during the Employment Period, neither Employee nor any Affiliate of Employee will, directly or indirectly, become a shareholder,
director, officer, agent, partner or employee of, or otherwise hold any ownership interest in, any person, firm or entity engaged
in any Competitive Business (as defined below), engage as a sole proprietor in any Competitive Business, act as a consultant to
or assist any of the foregoing or otherwise engage or participate in any Competitive Business; provided, however, that the foregoing
shall not prohibit the ownership by Employee of less than ten percent (10%) of the outstanding shares of the stock of any corporation
engaged in any Competitive Business, which shares are regularly traded on a national securities exchange or in any over-the-counter
market. For the purpose hereof, "Competitive Business" means the ownership, operation, development, marketing of the
services related to, or management of cellular therapeutics within the United States.

d.
Consideration, Relief, Reformation; Severability. The Company has specifically bargained for the covenants set forth in this
Section 7 in consideration for the compensation, experience, and information that Employee will gain or receive in connection
with his employment by the Company. Employee agrees that the covenants set forth herein will not preclude Employee from
engaging in any lawful profession, trade or business or from being gainfully employed necessary to provide Employee, his
family members and dependents a standard of living to which he and they have been accustomed and may expect. Employee
acknowledges and agrees that the restrictive covenants in this Section 6 have been specifically negotiated, are reasonable in
all respects, including, without limitation, their geographic scope and duration, and may be enforced by specific performance
or otherwise. Employee shall not raise any issue of reasonableness as a defense in any proceeding to enforce any of such
covenants. Notwithstanding the foregoing, in the event that a covenant included in this Agreement shall be deemed by any
court to be unreasonably broad in any respect, it shall be modified or limited in its geographic scope, duration or otherwise
to the extent necessary to make it reasonable while preserving its restrictive nature to the maximum degree possible and
shall be enforced accordingly; provided however, that if, notwithstanding the foregoing, a court of competent jurisdiction
shall hold any of the covenants contained in Sections 7 (a), (b) or (c) to be unenforceable (as so modified), then the
unenforceable covenant shall be deemed eliminated from the provisions of this Agreement for the purpose of those proceedings
to the extent necessary to permit the remaining covenants to be enforced so that the validity, legality or enforceability of
the remaining provisions of this Agreement shall not be affected thereby.

8.
Developments.

Employee
hereby assigns to the Company his entire right, title and interest in all know how, discoveries and improvements,
customer lists, trade secrets and ideas, writings and copyrightable material, which may be conceived by Employee
or developed or acquired by him during the term of this Agreement, which may pertain directly to the Company's business
and were developed with Company resources. Employee agrees to promptly and fully disclose in writing all such developments. Employee
will, upon the Company's request, execute, acknowledge and deliver to the Company all instruments
and do all other acts which are necessary or desirable to entitle the Company to all rights in the foregoing
and enable the Company to file and prosecute applications for, and to acquire, maintain and enforce all letters, trademark
registrations or copyrights with respect to the foregoing in all countries.

9.
Remedies.

Employee
acknowledges that any material breach of this Agreement will cause irreparable harm to the Company, that such harm will be difficult
if not impossible to ascertain, and that the Company shall be entitled to equitable relief, including injunction, against
any actual or threatened breach hereof, without bond and without liability should such relief be denied, modified or vacated.
Neither the right to obtain such relief nor the obtaining of such relief shall be exclusive of or preclude the
Company from any other remedy.

10.
Legal Counsel.

Employee
acknowledges that Employee has carefully read this Agreement and understands all of the terms hereof and that Employee
has been given the opportunity to discuss this Agreement with Employee's private legal counsel and
has availed himself of that opportunity to the extent Employee wishes to do so.

11. Notices.

All
notices, requests and other communications under this Agreement shall be in writing and shall be deemed to have been received
five business days after having been deposited in the United States Mail and enclosed in a registered or certified post-paid
envelope; one day after having been sent by overnight courier on a business day or otherwise at the open of
business on the next succeeding business day; when personally delivered or sent by facsimile communications equipment
of the sending party on a business day or otherwise at the open of business on the next succeeding business day; and, in
each case, addressed to the respective parties at the addresses stated below or to such other changed addresses
that the parties may have fixed by notice in accordance herewith.

If
to the Company:

Regen
BioPharma, Inc.

4700
Sprint Street, Suite 304

La
Mesa, CA 91942

Attn:
David Koos, CEO

 

If
to Employee:

Thomas
Ichim

9255
Towne Centre Drive, #450

San
Diego, CA 92121

 

12.
Waiver of Breach.

A
waiver by the Company or Employee of a breach of any provision of this Agreement by the other party shall
not operate or be construed as a waiver of any subsequent breach by the other party.

13. Entire
Agreement.

This
instrument contains the entire agreement of the parties with respect to the subject matter hereof and supersedes any
prior agreements of the parties with respect to the subject matter hereof. It may be changed only
by an agreement in writing signed by a party against whom enforcement of any waiver, change,
modification, extension or discharge is sought.

 14.
Applicable Law.

 The
terms and conditions of this Agreement shall be governed by and construed in accordance with the laws of the State or
California. Any action to enforce this Agreement shall be brought in the state courts located in San Diego County, State
of California.

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written. 

	 
	By: /s/
    David Koos
	David Koos
	Chief Executive Officer

 

 

	 
	By: /s/
    Thomas Ichim
	Thomas Ichim, PhD

 

    	 

    	 

    

 

Schedule
1

Employer:
Regen BioPharma, Inc.

 

Location:
Company Headquarters and Contracted Research Facilities

 

Description:

 

The
Chief Scientific Officer day to day duties include:

·

		•	Coordinating
                                         the company’s research projects;
	 	•	Sourcing Principal Researchers;
	 	•	Identifying intellectual property
                              relevant to the company’s interests;
	 	•	Identifying research facilities and
                              negotiating contracts with contract research organizations;
	 	•	Analyzing Scientific Data;
	 	•	Writing reports of Scientific Experiments;
	 	•	Submitting grant proposals and presenting
                              findings to various governmental agencies, including but not limited to the FDA

Position
Responsibilities:

 

1.
Plan, develop, organize, implement, direct and evaluate intellectual property for Company in-licensing.

 

2.
Coordinate all aspects of the company’s research activities.

 

3.
Source outside researchers, partners and facilities in order to conduct the company’s business with final approval regarding
the retention of researchers, entry into agreements with partners, or purchase or lease of facilities to be granted by the Company’s
CEO in his sole discretion.    .

 

4.
Advise, negotiate, manage and administer research contracts in which the company may enter.

 

5.
Lead and direct the development, communication and implementation of research related effective growth strategies and processes.

 

6.
Perform other duties as required. Perform other responsibilities as mandated by and any other pertinent local, state or federal
regulations.

 

VESTING
SCHEDULE FOR SIGNING SHARES

 

Signing
Shares may not be sold, transferred, assigned, pledged or otherwise encumbered or disposed of by Employee (“Transfer Restriction”)
except as follows:

 

Transfer
Restrictions shall no longer apply to the Signing Shares (“Milestone Shares”) upon the achievement of the following
events ( Milestones”) during the course of the Employee’s employment with the Company after 18 months.

 

		1.	Expansion
                                         of Scientific Advisor Board: Expand SAB to 15 members (10 points)

		2.	R&D
                                         relationships: initiate and manage relationships with 3 CROs, 3 manufacturers, 3 clinical
                                         sites and 1 academic collaboration (10 points)

		3.	Patents
                                         in licensed/filed/issued: 10 non provisional patents filed ( 10 points)

		4.	Securing
                                         lead researcher for each clinical trial ( 1 point) / Clinical trials: pre-clinical( 1
                                         point) phase 1 ( 1 pt) and phase 2 or efficacy finding ( 1 pt)

		5.	INDs
                                         filed ( 1 point) and INDs cleared ( 2 points) 

		6.	IP/Patents
                                         transactions ( e.g. : license agreements, product sales and co-development deals at a
                                         level acceptable to the Board of Directors=10pts.

 

Assuming
a total of 60 points are possible for vesting, a combination of the above points equal to 60 over an 18 month period results in
100% vesting. At the end of 18 months, should the total number of points amount to less than 60, vesting shall be reduced to that
number of points attained divided by 60, resulting in a percentage of shares vested. At the end of 18 months, all unvested shares
shall be forfeited . In the event of a change of control all shares shall be deemed fully vested.Exhibit
10.2

EMPLOYMENT
AGREEMENT BETWEEN REGEN BIOPHARMA, INC AND CHRISTINE ICHIM

THIS EMPLOYMENT
AGREEMENT (the "Agreement") dated as of January 14, 2015 is entered into between Regen BioPharma,
Inc., a Nevada corporation, (the "Company") and Christine Ichim ("Employee").

 

WITNESSETH:

WHEREAS, Employee
and the Company desire to enter into an agreement providing for the employment by the Company of Employee
upon the terms provided herein.

REPRESENTATIONS AND WARRANTIES

 

A)
Company hereby represents and warrants to Employee as follows;

(i)
Corporate Existence of Company. Company:

(a)
is a corporation duly formed, validly existing and in good standing under the laws of the State of Nevada and

(b)
has all requisite power and authority, and has all governmental licenses, authorizations, consents and approvals necessary to
execute and deliver this Agreement and to consummate the transactions contemplated by this Agreement.

 

(ii) No
Conflicts. None of the execution, delivery and performance of this Agreement by Company, or the consummation
or the transactions contemplated hereby and thereby

 

(a)
constitute or will constitute a violation of the organizational documents of Company,

(b)
constitutes or will constitute a breach or violation of, or a default (or an event which, with notice
or lapse of time or both, would constitute such a default) under, any indenture, mortgage,
deed of Company, loan agreement, lease or other agreement or instrument to which Company is a
party or by which Company or any of its properties may be bound,

(c)
violates or will violate any statute, law or regulation or any order, judgment, decree or injunction of any court
or Governmental Authority directed to Company or any of its properties in a proceeding to which
its property is or was a party.

 

(B)
Employee hereby represents and warrant to Company as follows:

(i)
No Conflicts. None of the execution, delivery and performance of this Agreement by Employee, or the consummation of the transactions
contemplated hereby and thereby

(a)
constitutes or will constitute a breach or violation of, or a default (or an event which, with notice or lapse of time or
both, would constitute such a default) under, any indenture, mortgage, deed of Trust, loan agreement, lease or other
agreement or instrument to which Employee is a party or by which Employee or any of its properties may be bound,

(b)
violates or will violate any statute, law or regulation or any order, judgment, decree or injunction of any court or Governmental
Authority directed to Employee or any of their properties in a proceeding to which its property is or was a party.

AGREEMENT:

NOW,
THEREFORE, in consideration of the foregoing and the mutual promises and agreements set forth herein, the parties hereto, intending
to be legally bound, hereby agree as follows:

1.
Employment. During the Employment Period (as defined in Section 2), the Company hereby employs Employee and Employee hereby
accepts employment.

2.
Term. The Term of this Agreement shall commence on January 14, 2015 and shall expire on January 13, 2018 unless sooner terminated
in accordance with the provisions of Section 6 hereof; provided, however, that the term of this Agreement may be extended by mutual
agreement. The period from the commencement of the term of this Agreement to the date of its expiration or sooner termination
shall be considered to be the “Employment Period" hereunder.

3.
Duties. Employee shall be granted the title of Director of Molecular Therapeutics of the Company subject to the authority
of the Company's Chief Executive Officer (the "CEO"), Employee shall perform such duties commensurate with his offices
and as directed by the CEO such duties to include, but not be limited to:

See
Schedule 1.

During
the Employment Period, Employee shall perform his duties hereunder in a diligent manner, subject to the provisions of Schedule
1 of this Agreement; devoting such amount of his business time, attention and efforts to the affairs of the Company within the
scope of his employment as is necessary for the proper rendition of such service and shall use his best efforts to promote the
best interests of the Company. Employee's services shall be rendered when and as required by the CEO and in accordance with his
instructions, direction and control.

It
is agreed that Employee will only devote such time as to effectively conduct duties and responsibilities associated with this
position pursuant to this Agreement.

4.
Compensation Salary. During the Employment Period, Company shall pay Employee salary at the rate of (i) $6,000 per month prorated
for any partial employment month ("Salary"). Salary shall be paid on a monthly basis (“Payday”) or, in the
event that Payday falls on a Saturday, Sunday or holiday, on the next business day. Salary may be paid, at the Company’s
sole discretion, either in

 

(a)
       cash, or

(b)
       shares of the Company’s common stock (“Stock Payment”)

 

Employee
acknowledges that any Stock Payments issued pursuant to this Agreement that are not registered pursuant to the Securities
Act of 1933 shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Securities
Act of 1933, and shall contain the following restrictive legend:

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

 

The
Company may register any Stock Payment pursuant to the Securities Act of 1933, but is not obligated to do so pursuant to this
Agreement.

 

5.
Benefits.

a.
During the Employment Period, Employee shall be entitled to participation in any profit sharing plan, retirement plan, group life
insurance plan or other insurance plan, medical expense plan, medical and dental insurance and other benefit arrangements maintained
by the Company for its employees generally and, if applicable, their family members. In addition, Employee shall be entitled to
two weeks paid vacation (“Vacation”) subject to (i) the completion of 12 full months of employment pursuant to this
Agreement and (ii) having given fourteen days prior notice to the Company of Employee’s intent to Vacation.

b.
Stock Compensation. Employee shall receive 2,500,000 newly issued common shares of the Company upon execution of this agreement
(“Signing Shares”). The shares shall be subject to a vesting schedule (see Schedule 2.).

Employee
acknowledges that any Signing Shares issued pursuant to this Agreement will not be registered pursuant to the Securities Act of
1933 , shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Securities
Act of 1933 and shall contain the following restrictive legend:

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

6.
Termination.

a.
Employee's employment hereunder shall terminate upon the earlier of:

(i)
the expiration of the Employment Period,

(ii)
the death of Employee,

(iii)
the expiration of a continuous period of thirty (30) calendar days during which Employee is unable to perform his material duties
due to physical or mental incapacity,

(iv)
termination by the Company due to “just cause,”

(v)
termination by Employee due to a material breach of this Agreement by the Company . The exercise of the right of the Company or
Employee to terminate this Agreement pursuant to clauses

(iv)
or (v) hereof, as the case may be, shall not abrogate the rights and remedies of the terminating party in respect of the breach
giving rise to such termination.

b.
"Just cause" hereunder shall be defined and limited to mean:

(i)
Employee's failure or refusal, as determined by either the CEO in his sole discretion, to perform specific directives of the CEO
which are consistent with the scope and nature of Employee's duties and responsibilities as set forth herein (including the duties
described in Section 3), which failure or refusal continues after notice thereof and a reasonable time to cure; such reasonable
time to be determined by the CEO.

(ii)
Employee's conviction for a felony or any crime involving moral turpitude, fraud, or misrepresentation, or the presentation of
proof satisfactory to the CEO in the exercise of its reasonable judgment of Employee's misappropriation or embezzlement of funds
or assets from the Company;

(iii)
any intentional act having the purpose and effect of injuring the reputation, business or business relationships of the Company
in any material respect; and

(iv)
any breach by Employee of any material provision of this Agreement, including, without limitation, the restrictive covenants contained
in Section 7 hereof.

c.
In the event of any dispute regarding the existence of Employee's incapacity hereunder, the matter wil1 be resolved by the determination
of a physician qualified to practice medicine in California selected by the CEO. For this purpose, Employee will submit to appropriate
medical examinations.

d.
If Employee's employment hereunder is terminated pursuant to Section 7, the Company shall have no further obligations or liabilities
hereunder.

7. Restrictive
Covenant.

a.
Non-disclosure. Employee has, and during the Employment Period will have, access to confidential information and trade secrets
of the Company and its subsidiaries (the "Confidential Information") that may include, among other things:

(i)
Financial information

(ii)
Supply and services information

(iii)
Marketing information

(iv)
Personnel information

(v)
Customer information

(vi)
Product information

(vii)
The Company’s procedures, systems, policies and processes of operation.

Employee
shall at all times during his employment by the Company and thereafter hold in strictest confidence any and all Confidential Information
that may have come or may come into Employee's possession or within Employee's knowledge. Employee agrees that neither he nor
any person or entity, directly or indirectly, controlled by or under common control with the Employee (an "Affiliate")will
for any reason, except in the course of performing his duties hereunder, for himself or any other person, use or disclose to anyone,
exclusive of Company employees, agents, representatives, or independent consultants to the Company or any of its subsidiaries
or Affiliates of the Company, any Confidential Information; provided, however, that Employee may disclose Confidential Information
which (i) has become generally available to the public other than as a result of a breach of this Agreement by Employee or (ii)
Employee is compelled to disclose pursuant to subpoena or an order by a court competent jurisdiction; provided that, if Employee
is so required to disclose any Confidential Information pursuant to the foregoing clause (ii), Employee shall provide advance
written notice to the Company, to the extent possible, to allow the Company to seek an appropriate protective order therefore
(iii) Potential advisors, employees, or investors of the Company where there is a reasonable expectation of confidentiality. All
Confidential Information shall remain the Company's property and shall be returned (or, at the Company's option, destroyed) upon
the Company's written request.

b.
Non-Solicitation of Employees. Employee agrees that from the date hereof and continuing for a period of three years following
the termination of this Agreement for whatever reason (the "Non-Compete Period"), neither Employee nor any Affiliate
of Employee will solicit or hire for employment any officer, director or employee of the Company who was employed by the Company
at any time within twelve months prior to the act of solicitation.

c.
Non-Competition. Employee agrees that, other than with the approval of the CEO, which approval shall not be unreasonably withheld,
during the Employment Period, neither Employee nor any Affiliate of Employee will, directly or indirectly, become a shareholder,
director, officer, agent, partner or employee of, or otherwise hold any ownership interest in, any person, firm or entity engaged
in any Competitive Business (as defined below), engage as a sole proprietor in any Competitive Business, act as a consultant to
or assist any of the foregoing or otherwise engage or participate in any Competitive Business; provided, however, that the foregoing
shall not prohibit the ownership by Employee of less than ten percent (10%) of the outstanding shares of the stock of any corporation
engaged in any Competitive Business, which shares are regularly traded on a national securities exchange or in any over-the-counter
market. For the purpose hereof, "Competitive Business" means the ownership, operation, development, marketing of the
services related to, or management of cellular therapeutics within the United States.

d.
Consideration, Relief, Reformation; Severability. The Company has specifically bargained for the covenants set forth in this
Section 7 in consideration for the compensation, experience, and information that Employee will gain or receive in connection
with his employment by the Company. Employee agrees that the covenants set forth herein will not preclude Employee from
engaging in any lawful profession, trade or business or from being gainfully employed necessary to provide Employee, his
family members and dependents a standard of living to which he and they have been accustomed and may expect. Employee
acknowledges and agrees that the restrictive covenants in this Section 6 have been specifically negotiated, are reasonable in
all respects, including, without limitation, their geographic scope and duration, and may be enforced by specific performance
or otherwise. Employee shall not raise any issue of reasonableness as a defense in any proceeding to enforce any of such
covenants. Notwithstanding the foregoing, in the event that a covenant included in this Agreement shall be deemed by any
court to be unreasonably broad in any respect, it shall be modified or limited in its geographic scope, duration or otherwise
to the extent necessary to make it reasonable while preserving its restrictive nature to the maximum degree possible and
shall be enforced accordingly; provided however, that if, notwithstanding the foregoing, a court of competent jurisdiction
shall hold any of the covenants contained in Sections 7 (a), (b) or (c) to be unenforceable (as so modified), then the
unenforceable covenant shall be deemed eliminated from the provisions of this Agreement for the purpose of those proceedings
to the extent necessary to permit the remaining covenants to be enforced so that the validity, legality or enforceability of
the remaining provisions of this Agreement shall not be affected thereby.

8.
Developments.

Employee
hereby assigns to the Company his entire right, title and interest in all know how, discoveries and
improvements, customer lists, trade secrets and ideas, writings and copyrightable material, which
may be conceived by Employee or developed or acquired by him during the term of this
Agreement, which may pertain directly to the Company's business and were developed with Company resources. Employee
agrees to promptly and fully disclose in writing all such developments. Employee will, upon
the Company's request, execute, acknowledge and deliver to the
Company all instruments and do all other acts which are necessary or desirable to entitle the
Company to all rights in the foregoing and enable the Company to file and prosecute applications for, and to acquire,
maintain and enforce all letters, trademark registrations or copyrights with respect to the foregoing
in all countries.

9.
Remedies.

Employee
acknowledges that any material breach of this Agreement will cause irreparable harm to the Company, that such harm will be difficult
if not impossible to ascertain, and that the Company shall be entitled to equitable relief, including injunction, against
any actual or threatened breach hereof, without bond and without liability should such relief be denied, modified or vacated.
Neither the right to obtain such relief nor the obtaining of such relief shall be exclusive of or preclude the
Company from any other remedy.

10.
Legal Counsel.

Employee
acknowledges that Employee has carefully read this Agreement and understands all of the terms hereof and that Employee
has been given the opportunity to discuss this Agreement with Employee's private legal counsel and
has availed himself of that opportunity to the extent Employee wishes to do so.

11. Notices.

All
notices, requests and other communications under this Agreement shall be in writing and shall be deemed to have been received
five business days after having been deposited in the United States Mail and enclosed in a registered or certified post-paid
envelope; one day after having been sent by overnight courier on a business day or otherwise at the open of
business on the next succeeding business day; when personally delivered or sent by facsimile communications equipment
of the sending party on a business day or otherwise at the open of business on the next succeeding business day; and, in
each case, addressed to the respective parties at the addresses stated below or to such other changed addresses
that the parties may have fixed by notice in accordance herewith.

If
to the Company:

Regen
BioPharma, Inc.

4700
Sprint Street, Suite 304

La
Mesa, CA 91942

Attn:
David Koos, CEO

 

If
to Employee:

Christine
Ichim

12685
Campo Road

Spring
Valley , CA 91978

 

12.
Waiver of Breach.

A
waiver by the Company or Employee of a breach of any provision of this Agreement by the other party shall
not operate or be construed as a waiver of any subsequent breach by the other party.

13. Entire
Agreement.

This
instrument contains the entire agreement of the parties with respect to the subject matter hereof and supersedes any
prior agreements of the parties with respect to the subject matter hereof. It may be changed only
by an agreement in writing signed by a party against whom enforcement of any waiver, change,
modification, extension or discharge is sought.

 14.
Applicable Law.

 The
terms and conditions of this Agreement shall be governed by and construed in accordance with the laws of the State or
California. Any action to enforce this Agreement shall be brought in the state courts located in San Diego County, State
of California.

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

	 
	By: /s/
    David Koos
	David Koos
	Chief Executive Officer

 

 

	 
	By: /s/
    Christine Ichim
	Christine Ichim, PhD

 

    	 

    	 

    

  

Schedule
1

Employer:
Regen BioPharma, Inc.

 

Location:
Company Headquarters and Contracted Research Facilities

 

Description:

 

The
Director of Molecular Therapeutics day to day duties include:

 

		•	Coordinating
                                         the company’s research projects;
	 	•	Sourcing Principal Researchers;
	 	•	Identifying intellectual property
                              relevant to the company’s interests;
	 	•	Identifying research facilities and
                              negotiating contracts with contract research organizations;
	 	•	Analyzing Scientific Data;
	 	•	Writing reports of Scientific Experiments;
	 	•	Submitting
grant proposals and presenting findings to various governmental agencies

 

Position
Responsibilities:

 

1.
Plan, develop, organize, implement, direct and evaluate intellectual property for Company.

 

2.
Coordinate/ conduct molecular therapeutic aspects of the company’s research activities.

 

3.
Source outside researchers, partners and facilities in order to conduct the company’s business with final approval regarding
the retention of researchers, entry into agreements with partners, or purchase or lease of facilities to be granted by the Company’s
CEO in his sole discretion.    .

 

4.
Manage research facility.

 

5.
Perform other duties as required. Perform other responsibilities as mandated by and any other pertinent local, state or federal
regulations. 

 

VESTING
SCHEDULE FOR SIGNING SHARES

 

Signing
Shares may not be sold, transferred, assigned, pledged or otherwise encumbered or disposed of by Employee (“Transfer Restriction”)
except as follows:

 

Transfer
Restrictions shall no longer apply to the Signing Shares (“Milestone Shares”) upon the achievement of the following
events ( Milestones”) during the course of the Employee’s employment with the Company after 18 months.

 

		1.	Papers
                                         published 3 peer reviewed equals 3.3 points per paper or 1 high profile peer reviewed
                                         journals ( impact factor greater than 6) =10 pts 

		2.	Presentations
                                         made at conventions 4 presentations =10 points or 2.5 pts per presentation

		3.	Pre-Clinical
                                         Studies initiated /completed =1 point for initiation, 2 pts for completion and 1 bonus
                                         point for completing 2 or more studies.

		4.	Intellectual
                                         property filed ( provisional/non-provisional apps) 1 point for each patent app

		5.	Small
                                         molecule identification, identifying = 1 point, testing for binding = 3 pts, testing
                                         for efficacy = 6 pts. 

		6.	Completion
                                         of crystal structure for NR2F6=10 pts 

 

Assuming
a total of 60 points are possible for vesting, a combination of the above points equal to 60 over an 18 month period results in
100% vesting. At the end of 18 months, should the total number of points amount to less than 60, vesting shall be reduced to that
number of points attained divided by 60, resulting in a percentage of shares vested. At the end of 18 months, all unvested shares
shall be forfeited . In the event of a change of control all shares shall be deemed fully vested.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]